BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00103831
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Phase 2
Completed
- Conditions
- Chronic Myeloid LeukemiaPhiladelphia-Positive Myeloid Leukemia
- Interventions
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00103844
- Locations
- 🇬🇧
Local Institution, Newcastle, Tyne and Wear, United Kingdom
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Leukemia, Myeloid, Chronic-phaseLeukemia, Lymphoblastic, Acute, Philadelphia-positive
- Interventions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00103701
- Locations
- 🇺🇸
Local Institution, Houston, Texas, United States
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
- First Posted Date
- 2005-01-14
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 124
- Registration Number
- NCT00101816
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Phase 2
Completed
- Conditions
- Transitional Cell CarcinomaBladder NeoplasmsKidney NeoplasmsUreter NeoplasmsBladder CancerNeoplasm, Bladder
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00101608
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand
🇨🇦Local Insitution, Toronto, Ontario, Canada
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Phase 2
Completed
- Conditions
- Chronic Myeloid LeukemiaPhiladelphia-Positive Myeloid Leukemia
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 387
- Registration Number
- NCT00101660
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
🇨🇭Local Instituion, Basel, Switzerland
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 197
- Registration Number
- NCT00101647
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Chronic Myeloid LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-positive
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 96
- Registration Number
- NCT00101595
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00099879
- Locations
- 🇳🇱
Local Insitution, Groningen, Netherlands
🇬🇧Local Institution, Manchester, United Kingdom
Phase I (PH I) Mad Refractory Solid Tumor Study
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00099606
- Locations
- 🇬🇧
Local Institution, Glasgow, Strathclyde, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath